



Finnrick Analytics
Finnrick.com
Austin, TX

Project 135221
Lab # 127757
Date Rec'd 7/29/2025
Report Issued 8/11/2025

Project
Sample Tesamorelin 5 mg FXQ4E5A

Certificate of Analysis



Analyte	Result	LOQ	Units	Method	Date	% of Label
Peptide Analysis						
Purity by area	99.82	0.5	%	HPLC-UV/MS	8/5/2025	
Purity by mass	5.22	0.5	mg	HPLC-UV/MS	8/5/2025	104.37
Spectral identification	Confirmed			HPLC-UV/MS	8/5/2025	

The data presented are from the analysis of the sample shown and meet Krause Analytical internal quality assurance criteria unless otherwise flagged.
Methods shown reference current Krause Analytical SOPs
ND - Not detected LOQ - limit of quantification
Copyright © 2025 Krause Analytical LLC. All rights reserved.

Respectfully submitted,

Mark C. Krause
Laboratory Director




krause analytical


Lab #: 127757 Tesamorelin 5 mg FXQ4E5A

Chromatogram

Response_



Time
Response_




Time

Krause Analytical, LLC 8127 Mesa Drive Suite B-206 Austin, TX 78759



Spectra



Method Summary

- 2 mL of purified water is added to the lyophilized powder in the vial, and the contents mixed to dissolve the lyophilized powder.
- An aliquot is taken from the vial and diluted to contain approximately 500 mg/L of the peptide.
- The diluted sample is analyzed by HPLC-UV-MS.
- The mass spectrum obtained is compared to an authentic standard of the peptide for identification.
- The total area of all of the peaks in the chromatogram is calculated, and the area of the peak of the peptide is divided by the total area to obtain the purity by area value, reported in percent.
- The area of the peptide is compared to the area of the peptide peak in the known standard to obtain a concentration in the solution. This concentration is used to calculate the total mass of peptide in the vial, which is compared to the stated mass (label claim) and reported as both total mass in the vial and as a percent of the label claim.

Krause Analytical, LLC 8127 Mesa Drive Suite B-206 Austin, TX 78759

Finnrick Analytics
Finnrick.com
Austin, TX




Project 135313
Lab # 128574
Date Rec'd 9/16/2025
Report Issued 9/30/2025

Project
Sample Retatrutide 5 mg NZW33MN

Certificate of Analysis

Analyte	Result	LOQ	Units	Method	Date	% of Label
Peptide Analysis						
Chromatographic purity	99.85	0.5	%	HPLC-UV/MS	9/24/2025	
Total peptide mass	4.88	0.5	mg	HPLC-UV/MS	9/24/2025	97.65
Retatrutide	Confirmed		mg	HPLC-UV-MS	9/24/2025	



The data presented are from the analysis of the sample shown and meet Krause Analytical internal quality assurance criteria unless otherwise flagged.
Methods shown reference current Krause Analytical SOPs
ND - Not detected LOQ - limit of quantification
Copyright © 2025 Krause Analytical LLC. All rights reserved.

Respectfully submitted,



Mark C. Krause
Laboratory Director



krause analytical

Lab #: 128574 Retatrutide 5 mg NZW33MN

Chromatogram




Time

Krause Analytical, LLC 8127 Mesa Drive Suite B-206 Austin, TX 78759



Mass spectrum/Reference Spectrum



Method Summary

- 2 mL of purified water is added to the lyophilized powder in the vial, and the contents mixed to dissolve the lyophilized powder.
- An aliquot is taken from the vial and diluted to contain approximately 500 mg/L of the peptide.
- The diluted sample is analyzed by HPLC-UV-MS.
- The mass spectrum obtained is compared to an authentic standard of the peptide for identification.
- The total area of all of the peaks in the chromatogram is calculated, and the area of the peak of the peptide is divided by the total area to obtain the chromatographic purity value, reported in percent.
- The area of the peptide is compared to the area of the peptide peak in the known standard to obtain a concentration in the solution. This concentration is used to calculate the total mass of peptide in the vial, which is compared to the stated mass (label claim) and reported as both total mass in the vial and as a percent of the label claim.

Krause Analytical, LLC 8127 Mesa Drive Suite B-206 Austin, TX 78759


Finnrick Analytics
Finnrick.com
Austin, TX



Project 135326
Lab # 128890
Date Rec'd 9/23/2025
Report Issued 10/5/2025

Project
Sample Retatrutide 30 mg kpdgrnr

Certificate of Analysis



Analyte	Result	LOQ	Units	Method	Date	% of Label
Peptide Analysis						
Chromatographic purity	99.73	0.5	%	HPLC-UV/MS	10/1/2025	
Total peptide mass	29.6	0.5	mg	HPLC-UV/MS	10/1/2025	98.6
Retatrutide	ID Confirmed			HPLC-UV-MS	10/1/2025	


The data presented are from the analysis of the sample shown and meet Krause Analytical internal quality assurance criteria unless otherwise flagged.
Methods shown reference current Krause Analytical SOPs
ND - Not detected LOQ - limit of quantification
Copyright © 2025 Krause Analytical LLC. All rights reserved.

Respectfully submitted,

Mark C. Krause
Laboratory Director




Chromatogram



Krause Analytical, LLC 8127 Mesa Drive Suite B-206 Austin, TX 78759



Mass spectrum/Reference Spectrum



Method Summary

- 2 mL of purified water is added to the lyophilized powder in the vial, and the contents mixed to dissolve the lyophilized powder.
- An aliquot is taken from the vial and diluted to contain approximately 500 mg/L of the peptide.
- The diluted sample is analyzed by HPLC-UV-MS.
- The mass spectrum obtained is compared to an authentic standard of the peptide for identification.
- The total area of all of the peaks in the chromatogram is calculated, and the area of the peak of the peptide is divided by the total area to obtain the chromatographic purity value, reported in percent.
- The area of the peptide is compared to the area of the peptide peak in the known standard to obtain a concentration in the solution. This concentration is used to calculate the total mass of peptide in the vial, which is compared to the stated mass (label claim) and reported as both total mass in the vial and as a percent of the label claim.

Krause Analytical, LLC 8127 Mesa Drive Suite B-206 Austin, TX 78759

Finnrick Analytics
Finnrick.com
Austin, TX



Project 135326
Lab # 128903
Date Rec'd 9/23/2025
Report Issued 10/5/2025

Project
Sample Retatrutide 40 mg 6x6xp3s

Certificate of Analysis



Analyte	Result	LOQ	Units	Method	Date	% of Label
Peptide Analysis						
Chromatographic purity	99.87	0.5	%	HPLC-UV/MS	10/1/2025	
Total peptide mass	38.0	0.5	mg	HPLC-UV/MS	10/1/2025	94.9
Retatrutide	ID Confirmed			HPLC-UV-MS	10/1/2025	

The data presented are from the analysis of the sample shown and meet Krause Analytical internal quality assurance criteria unless otherwise flagged.
Methods shown reference current Krause Analytical SOPs
ND - Not detected LOQ - limit of quantification
Copyright © 2025 Krause Analytical LLC. All rights reserved.


Respectfully submitted,

Mark C. Krause
Laboratory Director

8127 Mesa Drive Suite B-206 Austin, TX 78759




Chromatogram



Krause Analytical, LLC 8127 Mesa Drive Suite B-206 Austin, TX 78759



Mass spectrum/Reference Spectrum



Method Summary

- 2 mL of purified water is added to the lyophilized powder in the vial, and the contents mixed to dissolve the lyophilized powder.
- An aliquot is taken from the vial and diluted to contain approximately 500 mg/L of the peptide.
- The diluted sample is analyzed by HPLC-UV-MS.
- The mass spectrum obtained is compared to an authentic standard of the peptide for identification.
- The total area of all of the peaks in the chromatogram is calculated, and the area of the peak of the peptide is divided by the total area to obtain the chromatographic purity value, reported in percent.
- The area of the peptide is compared to the area of the peptide peak in the known standard to obtain a concentration in the solution. This concentration is used to calculate the total mass of peptide in the vial, which is compared to the stated mass (label claim) and reported as both total mass in the vial and as a percent of the label claim.

Krause Analytical, LLC 8127 Mesa Drive Suite B-206 Austin, TX 78759


Finnrick Analytics
Finnrick.com
Austin, TX



Project 135362
Lab # 129017
Date Rec'd 9/26/2025
Report Issued 10/9/2025

Project
Sample Retatrutide 10 mg nhvjyh

Certificate of Analysis



Analyte	Result	LOQ	Units	Method	Date	% of Label
Peptide Analysis						
Chromatographic purity	99.81	0.5	%	HPLC-UV/MS	10/6/2025	
Total peptide mass	9.15	0.5	mg	HPLC-UV/MS	10/6/2025	91.5
Retatrutide	ID Confirmed			HPLC-UV-MS	10/6/2025	

The data presented are from the analysis of the sample shown and meet Krause Analytical internal quality assurance criteria unless otherwise flagged.
Methods shown reference current Krause Analytical SOPs
ND - Not detected LOQ - limit of quantification
Copyright © 2025 Krause Analytical LLC. All rights reserved.


Respectfully submitted,

Mark C. Krause
Laboratory Director



Chromatogram


Response_



Krause Analytical, LLC 8127 Mesa Drive Suite B-206 Austin, TX 78759



Mass spectrum/Reference Spectrum



Method Summary

- 2 mL of purified water is added to the lyophilized powder in the vial, and the contents mixed to dissolve the lyophilized powder.
- An aliquot is taken from the vial and diluted to contain approximately 500 mg/L of the peptide.
- The diluted sample is analyzed by HPLC-UV-MS.
- The mass spectrum obtained is compared to an authentic standard of the peptide for identification.
- The total area of all of the peaks in the chromatogram is calculated, and the area of the peak of the peptide is divided by the total area to obtain the chromatographic purity value, reported in percent.
- The area of the peptide is compared to the area of the peptide peak in the known standard to obtain a concentration in the solution. This concentration is used to calculate the total mass of peptide in the vial, which is compared to the stated mass (label claim) and reported as both total mass in the vial and as a percent of the label claim.

Krause Analytical, LLC 8127 Mesa Drive Suite B-206 Austin, TX 78759


Finnrick Analytics
Finnrick.com
Austin, TX



Project 135362
Lab # 129105
Date Rec'd 9/26/2025
Report Issued 10/9/2025

Project
Sample Tirzepatide 10 mg msxj237

Certificate of Analysis



Analyte	Result	LOQ	Units	Method	Date	% of Label
Peptide Analysis						
Chromatographic purity	99.71	0.5	%	HPLC-UV/MS	10/9/2025	
Total peptide mass	9.42	0.5	mg	HPLC-UV/MS	10/9/2025	94.2
Tirzepatide	ID Confirmed			HPLC-UV-MS	10/9/2025	

The data presented are from the analysis of the sample shown and meet Krause Analytical internal quality assurance criteria unless otherwise flagged.
Methods shown reference current Krause Analytical SOPs
ND - Not detected LOQ - limit of quantification
Copyright © 2025 Krause Analytical LLC. All rights reserved.

Respectfully submitted,

Mark C. Krause
Laboratory Director


8127 Mesa Drive Suite B-206 Austin, TX 78759



krause analytical

Chromatogram

Response_




Time

Krause Analytical, LLC 8127 Mesa Drive Suite B-206 Austin, TX 78759



Mass spectrum/Reference Spectrum



Method Summary

- 2 mL of purified water is added to the lyophilized powder in the vial, and the contents mixed to dissolve the lyophilized powder.
- An aliquot is taken from the vial and diluted to contain approximately 500 mg/L of the peptide.
- The diluted sample is analyzed by HPLC-UV-MS.
- The mass spectrum obtained is compared to an authentic standard of the peptide for identification.
- The total area of all of the peaks in the chromatogram is calculated, and the area of the peak of the peptide is divided by the total area to obtain the chromatographic purity value, reported in percent.
- The area of the peptide is compared to the area of the peptide peak in the known standard to obtain a concentration in the solution. This concentration is used to calculate the total mass of peptide in the vial, which is compared to the stated mass (label claim) and reported as both total mass in the vial and as a percent of the label claim.

Krause Analytical, LLC 8127 Mesa Drive Suite B-206 Austin, TX 78759



Proudly Owned and Operated in the USA

Searchable via: FreedomDiagnosticsTesting.com

Product	Tesamorelin 10mg
Net Peptide Content	9.1 mg
Identity	Tesamorelin

Certificate of Analysis



Assession Number	2508150007
Client	Finnrick
Search Code	finn2508150007

Received Date:	8/15/2025
Reported Date:	8/16/2025

Lot	VAUX97F
Purity	99.41%
Appearance	White Lyophilized Powder

All Chemical Analysis was performed by HPLC with UV Detection Coupled with Mass Spectrometry

Mass Identification	Result
Tesamorelin	99.41%



Stephen Schmidt

COA: 2508150007

Stephen Schmidt
Principle Chemist

The peptide purity analysis reported here was conducted using LCMS/MS under standard laboratory conditions. This analysis is intended for informational purposes only and is specific to the sample(s) provided. The peptides tested are intended for research use only and are not approved for human or veterinary use, diagnostic, therapeutic, or clinical applications. Results should be interpreted by qualified professionals within the scope of the intended research. The accuracy and reliability of the test may be influenced by sample integrity, handling, and other experimental variables.

Searchable via: FreedomDiagnosticsTesting.com

Contact at: Admin@FreedomDiagnostics.net



Proudly Owned and Operated in the USA

Searchable via: FreedomDiagnosticsTesting.com

Product	Retatrutide 20mg
Net Peptide Content	20.80 mg
Identity	Retatrutide

Certificate of Analysis




Assession Number	2508290028
Client	Finnrick
Search Code	finn2508290028

Received Date:	8/29/2025
Reported Date:	9/1/2025

Lot	EHDDDP
Purity	99.92%
Appearance	White Lyophilized Powder

All Chemical Analysis was performed by HPLC with UV Detection Coupled with Mass Spectrometry

Mass Identification	Result
Retatrutide	99.92%



Stephen Schmidt

Stephen Schmidt
Principal Chemist

COA: 2508290028

The peptide purity analysis reported here was conducted using LCMS/MS under standard laboratory conditions. This analysis is intended for informational purposes only and is specific to the sample(s) provided. The peptides tested are intended for research use only and are not approved for human or veterinary use, diagnostic, therapeutic, or clinical applications. Results should be interpreted by qualified professionals within the scope of the intended research. The accuracy and reliability of the test may be influenced by sample integrity, handling, and other experimental variables.

 Powered by BioTools	Report #: IF-824-QSA-TR006-2025-97-10
	Page 1 of 2
Title: Certificate of Analysis (CoA)	

Date: 10/06/2025
Date Tested: 10/06/2025
Customer: Finnrick
Testing material: Tirzepatide
Lot Number: YAN4WNC
BT Sample ID: 005000036181229
Labeled Peptide
Content/Potency: 60 mg
Storage: R.T.
Packing material: Clear glass vial with white label, silver crimp and light purple cap
Labeled as: Tirzepatide
Manufacturer: N/A
Testing Purpose: FTIR and HPLC analysis for the identification, purity, potency and composition of a peptide product. It does not provide information on particulate matter, microbial contamination or presence of endotoxins.

Test	Method	Specification	Result
General Appearance	USP <630>	White powder	White powder
Mass	USP <41>	As recorded	113.6 mg
FTIR Identification and Composition Analysis	USP <197A>	Sample spectrum should confirm the content of peptide via characteristic bands	FTIR sample spectrum confirms the presence of peptide with addition of excipient(s)/fillers such as mannitol.
HPLC Purity of Peptide Assay	USP <621>	Specifications: ≥ 98 %	99.6 %
HPLC Potency Assay	USP <621>	Specifications: 95 – 105% of 60 mg	75.6 mg (126.1%)

The results of the CoA relate only to the item(s) tested and applied to the sample as received.

Kimberly Quinn, MS

Digitally signed by Kimberly Quinn, MS
DN: O=BioTools Inc, CN=Kimberly Quinn, MS*, E=kquinn@biotools.us
Reason: I am approving this document
Location: West Palm Beach, FL USA
Date: 2025.10.10 11:44:48-04'00'
Foxit PDF Reader Version: 2025.2.0

Kimberly Quinn, MS

Lab Manager

BTLabs

Andrea Castro, AS

Digitally signed by Andrea Castro, AS
DN: OU=BTLabs, O=BioTools Inc, CN=Andrea Castro, AS*, E=acastro@biotools.us
Reason: I am the author of this document
Location: West Palm Beach, FL USA
Date: 2025.10.10 11:51:25-04'00'
Foxit PDF Reader Version: 2025.2.0

Andrea Castro, AS

Scientist-I

BTLabs



Powered by BioTools


Report #:
IF-824-QSA-TR006-2025-97-10

Page 2 of 2


Title:

Certificate of Analysis (CoA)

FTIR ID and Composition Analysis: Tirzepatide Lot YAN4WNC



HPLC Purity and Potency Assay @ 280 nm: Tirzepatide Lot YAN4WNC



Tirzepatide lot YAN4WNC @ 280 nm		
Peak #:	Retention Time (min)	Area (mAU*s)
1	12.718	28.3
2	13.866	6243.3

 Powered by BioTools	Report #: IF-824-QSA-TR006-2025-97-28
	Page 1 of 2
Title: Certificate of Analysis (CoA)	

Date: 10/06/2025
Date Tested: 10/06/2025
Customer: Finnrick
Testing material: Tirzepatide
Lot Number: MH7ZVW9
BT Sample ID: 005000036183638
Labeled Peptide
Content/Potency: 30 mg
Storage: R.T.
Packing material: Clear glass vial with white label, green crimp and light pink cap
Labeled as: Tirzepatide
Manufacturer: N/A
Testing Purpose: FTIR and HPLC analysis for the identification, purity, potency and composition of a peptide product. It does not provide information on particulate matter, microbial contamination or presence of endotoxins.

Test	Method	Specification	Result
General Appearance	USP <630>	White powder	White powder
Mass	USP <41>	As recorded	74 mg
FTIR Identification and Composition Analysis	USP <197A>	Sample spectrum should confirm the content of peptide via characteristic bands	FTIR sample spectrum confirms the presence of peptide with addition of excipient(s)/fillers such as mannitol.
HPLC Purity of Peptide Assay	USP <621>	Specifications: ≥ 98 %	99.5 %
HPLC Potency Assay	USP <621>	Specifications: 95 – 105% of 30 mg	34.8 mg (116.1 %)

The results of the CoA relate only to the item(s) tested and applied to the sample as received.

Kimberly Quinn, MS

Digitally signed by Kimberly Quinn, MS
DN: O=BioTools Inc, CN=Kimberly Quinn, MS, E=kquinn@biotools.us
Reason: I am approving this document
Location: West Palm Beach, FL USA
Date: 2025.10.10 11:48:06-04'00'
Foxit PDF Reader Version: 2025.2.0

Kimberly Quinn, MS

Lab Manager

BTLabs

Andrea Castro, AS

Digitally signed by Andrea Castro, AS
DN: OU=BTLabs, O=BioTools Inc, CN=Andrea Castro, AS, E=acastro@biotools.us
Reason: I am the author of this document
Location: West Palm Beach, FL USA
Date: 2025.10.10 11:51:14-04'00'
Foxit PDF Reader Version: 2025.2.0

Andrea Castro, AS

Scientist-I

BTLabs



Powered by BioTools


Report #:
IF-824-QSA-TR006-2025-97-28

Page 2 of 2


Title:

Certificate of Analysis (CoA)

FTIR ID and Composition Analysis: Tirzepatide Lot MH7ZVW9



HPLC Purity and Potency Assay @ 280 nm: Tirzepatide Lot MH7ZVW9



Tirzepatide Lot MH7ZVW9 @ 280 nm		
Peak #:	Retention Time (min)	Area (mAU*s)
1	12.608	20.2
2	13.792	4432.9

TEST REPORT



E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #58407

Testing ordered > 21 FEB '25

Sample received > 24 FEB '25

Client wslabus@gmail.com

Sample IGF-1LR3 1mg

Manufacturer Wuhan Wansheng Bio

Batch WWB-0225

Sample description >

See picture or pictures attached.

Tests requested >

Assessment of a peptide vial or vials.

Results >



IGF-1 LR3	1.38 mg
Purity	99.806%

Comments >

Analysis conducted > 25 FEB 2025

Signature >

A handwritten signature in black ink, appearing to be 'Jano' or similar, located next to the 'Signature >' label.

Verify this test at www.janoshik.com/verify/ with the following unique key

XDR1H56SNVZN

TEST REPORT



E-mail: info@janoshik.com

Web: www.janoshik.com

Task Number #63280

Testing ordered > 18 APR '25

Sample received > 24 APR '25

Client wslabus@gmail.com

Sample HCG 10000iu

Manufacturer Wuhan Wansheng Bio

Batch WWB-042025

Sample description >

See picture or pictures attached.

Tests requested >

Assessment of a peptide vial or vials.

Results >



HCG	10819 IU

Comments >

Immunoassay.

Analysis conducted > 27 APR 2025

Signature >

Verify this test at www.janoshik.com/verify/ with the following unique key

C5GVXQLCBLB4

TEST REPORT



E-mail: info@janoshik.com

Web: www.janoshik.com

Task Number #63281

Testing ordered > 18 APR '25

Sample received > 24 APR '25

Client wslabus@gmail.com

Sample SS-31 50mg

Manufacturer Wuhan Wansheng Bio

Batch WWB-042025

Sample description >

See picture or pictures attached.

Tests requested >

Assessment of a peptide vial or vials.

Results >



SS-31	62.81 mg
Purity	99.836%

Comments >

Analysis conducted > 28 APR 2025

Signature >



Verify this test at www.janoshik.com/verify/ with the following unique key

A91JTXE3MTYG

TEST REPORT



E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #64095

Testing ordered > 05 MAY '25

Sample received > 05 MAY '25

Client wslabus@gmail.com

Sample Tirzepatide 100mg

Manufacturer Wuhan Wansheng Bio

Batch WWB-0506

Sample description >

See picture or pictures attached.

Tests requested >

Assessment of a peptide vial or vials.

Results >



Tirzepatide	111.64 mg
Purity	99.476%

Comments >

Analysis conducted > 06 MAY 2025

Signature >

Verify this test at www.janoshik.com/verify/ with the following unique key

4TKJZZKWDF9

TEST REPORT



E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #64096

Testing ordered > 05 MAY '25

Sample received > 05 MAY '25

Client wslabus@gmail.com

Sample Selank 10mg

Manufacturer Wuhan Wansheng Bio

Batch WWB-0506

Sample description >

See picture or pictures attached.

Tests requested >

Assessment of a peptide vial or vials.

Results >



Selank	12.80 mg
Purity	99.572%

Comments >

Analysis conducted > 06 MAY 2025

Signature >

A handwritten signature in black ink, appearing to be 'Jano' or similar, located next to the 'Signature >' label.

Verify this test at www.janoshik.com/verify/ with the following unique key

A96G2Y8LDCGK

TEST REPORT



E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #64098

Testing ordered > 05 MAY '25

Sample received > 05 MAY '25

Client wslabus@gmail.com

Sample Semaglutide 20mg

Manufacturer Wuhan Wansheng Bio

Batch WWB-0506

Sample description >

See picture or pictures attached.

Tests requested >

Assessment of a peptide vial or vials.

Results >



Semaglutide	20.68 mg
Purity	99.378%

Comments >

Analysis conducted > 06 MAY 2025

Signature >

A handwritten signature in black ink, appearing to be 'Jano' or similar, written over the 'Signature >' label.

Verify this test at www.janoshik.com/verify/ with the following unique key

9IPI46357RYL

TEST REPORT



E-mail: info@janoshik.com

Web: www.janoshik.com

Task Number #66682

Testing ordered > 28 MAY '25

Sample received > 29 MAY '25

Client wslabus@gmail.com

Sample CJC-1295 without DAC 5mg + Ipamorelin 5mg

Manufacturer Wuhan Wansheng Bio

Batch WWB-062025

Sample description >

See picture or pictures attached.

Tests requested >

Assessment of a peptide vial or vials.

Results >



CJC-1295 (mod GRF 1-29)	5.22 mg
Ipamorelin	5.74 mg

Comments >

Analysis conducted > 05 JUN 2025

Signature >

Verify this test at www.janoshik.com/verify/ with the following unique key

MR9RWZYIM5PV

TEST REPORT



E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #66683

Testing ordered > 28 MAY '25

Sample received > 29 MAY '25

Client wslabus@gmail.com

Sample KLOW 80mg

Manufacturer Wuhan Wansheng Bio

Batch WWB-062025

Sample description >

See picture or pictures attached.

Tests requested >

Assessment of a peptide vial or vials.

Results >



TB-500 (TB-4)	10.77 mg
BPC-157	11.94 mg
GHK-Cu	53.78 mg

Comments >

KPV: 10.05 mg.

Analysis conducted > 05 JUN 2025

Signature >



Verify this test at www.janoshik.com/verify/ with the following unique key

1J45T6SPTB6Q

TEST REPORT



E-mail: info@janoshik.com

Web: www.janoshik.com

Task Number #75248

Testing ordered > 09 AUG '25

Sample received > 12 AUG '25

Client wslabus@gmail.com

Sample BPC-157 5mg+TB500 5mg Blend BB10

Manufacturer Wuhan Wansheng Bio

Batch WWB-0818

Sample description >

See picture or pictures attached.

Tests requested >

Assessment of a peptide vial or vials.

Results >



BPC-157	5.82 mg; 5.73 mg.
TB-500 (TB4)	5.25 mg; 5.20 mg.

Comments >

Analysis conducted > 18 AUG 2025

Signature >

A handwritten signature in black ink, appearing to be 'Jano' or similar, located next to the 'Signature >' label.

Verify this test at www.janoshik.com/verify/ with the following unique key

JERGJ2DL74X6

TEST REPORT



E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #75251

Testing ordered > 09 AUG '25

Sample received > 12 AUG '25

Client wslabus@gmail.com

Sample Tirzepatide 30mg TR30

Manufacturer Wuhan Wansheng Bio

Batch WWB-0818

Sample description >

See picture or pictures attached.

Tests requested >

Assessment of a peptide vial or vials.

Results >



Tirzepatide	37.19 mg; 32.17 mg.
Purity	99.956%; 99.929%.

Comments >

Analysis conducted > 19 AUG 2025

Signature >

Verify this test at www.janoshik.com/verify/ with the following unique key

SB33APXYFRQZ

TEST REPORT



E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #75753

Testing ordered > 18 AUG '25

Sample received > 20 AUG '25

Client wslabus@gmail.com

Sample Retatrutide 30mg

Manufacturer Wuhan Wansheng Bio

Batch WWB-0820

Sample description >

See picture or pictures attached.

Tests requested >

Assessment of a peptide vial or vials.

Results >



Retatrutide	35.86 mg; 35.75 mg.
Purity	99.920%; 99.923%.

Comments >

Analysis conducted > 22 AUG 2025

Signature >

Verify this test at www.janoshik.com/verify/ with the following unique key

X5EU4SYLZN7X

TEST REPORT



E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #75754

Testing ordered > 18 AUG '25

Sample received > 20 AUG '25

Client wslabus@gmail.com

Sample cagrilintide 5mg+Semaglutide 5mg Blend

Manufacturer Wuhan Wansheng Bio

Batch WWB-0820

Sample description >

See picture or pictures attached.

Tests requested >

Assessment of a peptide vial or vials.

Results >



Semaglutide	5.21 mg; 5.07 mg.
Cagrilintide	5.60 mg; 5.42 mg.

Comments >

Analysis conducted > 21 AUG 2025

Signature >

Verify this test at www.janoshik.com/verify/ with the following unique key

G7LHTXCJKETH

TEST REPORT



E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #75757

Testing ordered > 18 AUG '25

Sample received > 20 AUG '25

Client wslabus@gmail.com

Sample Retatrutide 5mg+cagrilintide 5mg Blend

Manufacturer Wuhan Wansheng Bio

Batch WWB-0820

Sample description >

See picture or pictures attached.

Tests requested >

Assessment of a peptide vial or vials.

Results >



Retatrutide	5.21 mg; 5.28 mg.
Cagrilintide	5.17 mg; 5.27 mg.

Comments >

Analysis conducted > 21 AUG 2025

Signature >

Verify this test at www.janoshik.com/verify/ with the following unique key

HGC1J4VS3PJT